biotech · Solid Tumors · Pancreatic Cancer · MREO
MEREO BIOPHARMA GROUP
Mereo BioPharma Group plc
MEREO BIOPHARMA GROUP is a biotech organization headquartered in LONDON, USA. It trades on NYSE under ticker MREO. Primary therapeutic focus areas include Solid Tumors, Pancreatic Cancer, Osteogenesis Imperfecta, Metasta
4TH FLOOR, ONE, LONDON, USA HQ
4 Employees
Public company Type
MREO · NYSE Ticker
Company details
- Status
- Public
- HQ
- 4TH FLOOR, ONE, LONDON, USA
- Employees
- 4
- Programs
- 47
- Drugs
- 22
- Patents
- 18
BCT197 Part A
Phase 2 · small molecule · Acute Kidney Injury
BCT197 Part A for Acute Kidney Injury is a Phase 2 program (small_molecule) at Mereo BioPharma Group plc with 1 ClinicalTrials.gov record(s).
Internal code CBCT197A2202
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Mereo BioPharma Group plc
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Acute Kidney Injury
- Status
- terminated
- Trials
- 1